Allogeneic BCMA CAR-T Cell Therapy for the Treatment of Multiple Myeloma
Time: 3:30 pm
day: Day One
Details:
- Developing the first allogeneic cell therapy for R/R multiple myeloma – from
bench to bedside - Enhancing potency and persistence of allogeneic BCMA CAR-T cells with TurboCARs
- Testing the promise of TurboCAR technology in the clinic
